278 related articles for article (PubMed ID: 36402993)
1. A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
Cantoni N; Sommavilla R; Seitz P; Kulenkampff E; Kahn S; Lambert JF; Schmidt A; Zenhaeusern R; Balabanov S
BMC Cancer; 2022 Nov; 22(1):1192. PubMed ID: 36402993
[TBL] [Abstract][Full Text] [Related]
2. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
3. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
5. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
6. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
Breccia M; Chiodi F; Nardozza AP; Valsecchi D; Perrone V; Sangiorgi D; Giacomini E; Rendace MC; Coco P; Premoli E; Degli Esposti L
Adv Ther; 2023 Mar; 40(3):961-974. PubMed ID: 36562943
[TBL] [Abstract][Full Text] [Related]
7. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
9. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Milojkovic D; Cross NCP; Ali S; Byrne J; Campbell G; Dignan FL; Drummond M; Huntly B; Marshall S; McMullin MF; Neelakantan P; Raghavan M; Sivakumaran M; Tighe J; Wandroo F; Willis F; Glen F; Fildes L; Collington SJ; Ryan J; Clark RE; Mead AJ
Br J Haematol; 2021 Jan; 192(1):62-74. PubMed ID: 32449159
[TBL] [Abstract][Full Text] [Related]
10. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
[No Abstract] [Full Text] [Related]
11. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
12. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
13. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Slezáková K; Mistrík M; Bátorová A
Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
[TBL] [Abstract][Full Text] [Related]
16. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S; Eskazan AE; Suzan V; Savci S; Erdogan Ozunal I; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Erbilgin Y; Iseri SA; Ar MC; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Hematology; 2018 May; 23(4):212-220. PubMed ID: 28990873
[TBL] [Abstract][Full Text] [Related]
17. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
18. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
Khoury HJ; Bixby DL
Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
[TBL] [Abstract][Full Text] [Related]
19. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
